Literature DB >> 9733888

Cell surface proteoglycans are necessary for A27L protein-mediated cell fusion: identification of the N-terminal region of A27L protein as the glycosaminoglycan-binding domain.

J C Hsiao1, C S Chung, W Chang.   

Abstract

We previously showed that vaccinia virus infection of BSC40 cells was blocked by soluble heparin, suggesting that cell surface heparan sulfate mediates vaccinia virus binding (C.-S. Chung, J.-C. Hsiao, Y. -S. Chang, and W. Chang, J. Virol. 72:1577-1585, 1998). In this study, we extended our previous work and demonstrated that soluble A27L protein bound to heparan sulfate on cells and interfered with vaccinia virus infection at a postbinding step. In addition, we investigated the structure of A27L protein that provides for its binding to heparan sulfate on cells. A mutant of A27L protein, named D-A27L, devoid of a cluster of 12 amino acids rich in basic residues, was constructed. In contrast to the soluble A27L protein, purified D-A27L protein was inactive in all of our assays, including binding to heparin in vitro, binding to heparan sulfate on cells, and the ability to block virus infection. These data demonstrated that the N-terminal region acts as a glycosaminoglycan (GAG)-binding domain critical for A27L protein binding to cells. Previously A27L protein was thought to be involved in fusion of virus-infected cells induced by acid treatment. When we investigated whether cell surface GAGs also participate in A27L-dependent fusion, our results indicated that soluble A27L protein blocked cell fusion, whereas D-A27L protein did not. Taken together, the results therefore demonstrated that A27L-mediated cell fusion is triggered by its interaction with cell surface GAGs through the N-terminal domain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733888      PMCID: PMC110218     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Neutralizing antibodies specific for glycoprotein H of herpes simplex virus permit viral attachment to cells but prevent penetration.

Authors:  A O Fuller; R E Santos; P G Spear
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

2.  Anti-glycoprotein D antibodies that permit adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the cell surface.

Authors:  A O Fuller; P G Spear
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

3.  Mapping and nucleotide sequence of the vaccinia virus gene that encodes a 14-kilodalton fusion protein.

Authors:  J F Rodriguez; M Esteban
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

4.  Inducible gene expression from vaccinia virus vectors.

Authors:  J F Rodriguez; G L Smith
Journal:  Virology       Date:  1990-07       Impact factor: 3.616

5.  Structure of vaccinia virus early promoters.

Authors:  A J Davison; B Moss
Journal:  J Mol Biol       Date:  1989-12-20       Impact factor: 5.469

6.  Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion.

Authors:  W H Cai; B Gu; S Person
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

7.  Soluble forms of herpes simplex virus glycoprotein D bind to a limited number of cell surface receptors and inhibit virus entry into cells.

Authors:  D C Johnson; R L Burke; T Gregory
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

8.  A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate.

Authors:  C S Chung; J C Hsiao; Y S Chang; W Chang
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

9.  Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus.

Authors:  J F Rodriguez; R Janeczko; M Esteban
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

10.  A single point mutation of Ala-25 to Asp in the 14,000-Mr envelope protein of vaccinia virus induces a size change that leads to the small plaque size phenotype of the virus.

Authors:  S C Gong; C F Lai; S Dallo; M Esteban
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

View more
  54 in total

1.  Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus.

Authors:  M I Vázquez; M Esteban
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation.

Authors:  A P Byrnes; D E Griffin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  The fusion domain of HIV gp41 interacts specifically with heparan sulfate on the T-lymphocyte cell surface.

Authors:  J Cladera; I Martin; P O'Shea
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

Review 4.  Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.

Authors:  Allison H Bartlett; Pyong Woo Park
Journal:  Expert Rev Mol Med       Date:  2010-02-01       Impact factor: 5.600

5.  Vaccinia mature virus fusion regulator A26 protein binds to A16 and G9 proteins of the viral entry fusion complex and dissociates from mature virions at low pH.

Authors:  Shu-Jung Chang; Ao-Chun Shih; Yin-Liang Tang; Wen Chang
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

6.  Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex.

Authors:  Suany Ojeda; Arban Domi; Bernard Moss
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

7.  Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo.

Authors:  C L Lin; C S Chung; H G Heine; W Chang
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

8.  The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion.

Authors:  Alan C Townsley; Tatiana G Senkevich; Bernard Moss
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Myxoma and vaccinia viruses bind differentially to human leukocytes.

Authors:  Winnie M Chan; Eric C Bartee; Jan S Moreb; Ken Dower; John H Connor; Grant McFadden
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

10.  Appearance of the bona fide spiral tubule of ORF virus is dependent on an intact 10-kilodalton viral protein.

Authors:  D Spehner; S De Carlo; R Drillien; F Weiland; K Mildner; D Hanau; H-J Rziha
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.